INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY
https://doi.org/10.21518/2079-701X-2017-12-112-117
Abstract
The article is devoted to the innovative drug to treat chronic cardiac insufficiency – a combination of sakubitril neprilysin inhibitor and first type angiotension II receptor antagonist valsartan (sacubitril/valsartan). Study results are provided in which a combination of sacubitril/valsartan demonstrated effectiveness in patients with arterial hypertension as well as with cardiac insufficiency. Advantages of a combination of sacubitril/valsartan as compared to other drugs affecting components of rennin-angiotension-aldosteron system from the point of view of safety and effectiveness in patients with cardiac insufficiency are demonstrated.
About the Author
N. A. Jaiani
Evdokimov Moscow State Medical and Stomatologic University of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
References
1. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs, 2003, 63: 2185-2202.
2. Kentsch M, Otter W. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitiors. Drugs R D, 1999 Apr, 1(4): 331-338.
3. Cruden NL, Fox KA, Ludlam CA et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension, 2004, 44: 913-918.
4. Rademaker MT, Charles CJ, Espiner EA et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond), 1996, 91: 283-291.
5. Wilkinson IB, McEniery CM, Bongaerts KH et al. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol, 2001, 52: 159-164.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med, 1998, 339: 321-328.
7. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs, 2003, 63: 2185-2202.
8. Mukoyama M, Nakao K, Obata K. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun, 1991, 180: 431-436.
9. Protter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens, 1996 May, 9(5): 432-436.
10. Corti R, Burnett JC, Rouleau JL et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation, 2001, 104: 1856-1862.
11. Mangiafico S, Costello-Boerrigter LC, Andersen IA et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal, 2013, 34: 886-893.
12. Grantham JA, Borgeson DD, Burnett JC. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol, 1997, 92: 1077-1083.
13. Maeda K, Takayoshi T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 1998, 135: 825-832.
14. Muders F, Kromer EP, Griese DP et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J, 1997, 134: 442-449.
15. Tonne JM, Campbell JM, Cataliotti A et al. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem, 2011: 57864-57873.
16. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol, 1998, 274: 63-72.
17. De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci, 1981, 28: 89-94.
18. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol, 1998, 32(Suppl. 3): S22-S28.
19. Chauhan SD, Hobbs AJ, Ahluwalia A. C-type natriuretic peptide: new candidate for endothelium-derived hyperpolarising factor. Int J Biochem Cell Biol, 2004, 36: 1878-1881.
20. Ichiki T, Huntley BK, Heublein DM et al. Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem, 2011, 57: 40-47.
21. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation, 2004, 109: 594-600.
22. Belluardo P, Cataliotti A, Bonaiuto L et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol, 2006, 291: H1529-H1535.
23. Macheret F, Heublein D, Costello-Boerrigter LC et al. Human hypertension is characterized by a lack of activation of the anti-hypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol, 2011, 57: 1386-1395.
24. Hawkridge AM, Heublein DM, Bergen HR 3rd et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA, 2005, 102: 17442-17447.
25. Niederkofler EE, Kiernan UA, O’Rear J et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail, 2008, 1: 258-264.
26. Miller WL, Phelps MA, Wood CM et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail, 2011, 4: 355-360.
27. Dries DL, Victor RG, Rame J et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation, 2005, 112: 2403–2410.
28. Chan JC, Knudson O, Wu F et al. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA, 2005, 102: 785-790.
29. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis, 2005, 47: 320-332.
30. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325: 293-302.
31. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA, 1995, 273: 1450-1456.
32. Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 2000, 356(9230): 615-620.
33. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation, 2002, 106: 920-926.
34. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004 February 1, 17(Issue 2): 103-111.
35. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345: 1667-1675.
36. Pfeffer MA, Swedberg K, Granger CB, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362(9386): 759-66, 1667-1675.
37. McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function. taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362(9386): 767-771.
38. Gu J, Noe A, Chandra P et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol, 2010, 50: 401-414.
39. Hegde LG, Yu C, Renner T et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol, 2011, 57: 495-504.
40. Ruilope LM, Dukat A, Buhm M et al. Blood pressure reduction with LCZ696, a novel dual acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet, 2010, 375: 1255-1266.
41. Solomon SD, Zile M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 2012, 380(9851): 1387-1395.
42. McMurray JJ, Packer M, Desai AS et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med, 2014, 371: 993-1004.
43. http://www.escardio.org/about/press/press-releases/pr-14/Pages/paradigm-hf-trial-stopped-early-for-benefit.aspx.
44. Desai AS, Vardeny O, Claggett B et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol, 2017 Jan 1, 2(1): 79-85.
45. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность, 2013, 81(7): 379-472.
46. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail, 2016, 18(8): 891-975.
47. Seferovic JP, Claggett B, Seidelmann SB et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol, 2017 May, 5(5): 333-340.
48. EMA, New medicine to treat heart failure recommended for approval. Available at: http:// www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/ human/ 004062/WC500197538.pdf.
49. FDA. FDA approves new drug to treat heart failure. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm453845. htm.
50. https://www.rlsnet.ru/mnn_index_id_6718.htm.
51. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016, 102(17): 1342-1347.
Review
For citations:
Jaiani NA. INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY. Meditsinskiy sovet = Medical Council. 2017;(12):112-117. (In Russ.) https://doi.org/10.21518/2079-701X-2017-12-112-117
Views:
858
Email this article 